This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dignam, J. J. Articles by Kocherginsky, M. N. Search for Related Content PubMed Articles by Dignam, J. J. Articles by Kocherginsky, M. N. Social Bookmarking                            What's this?

Choice and Interpretation of Statistical Tests Used When Competing Risks Are Present

James J. Dignam, Maria N. Kocherginsky

From the Department of Health Studies, The University of Chicago, Chicago, IL

Corresponding author: James J. Dignam, PhD, 5841 South Maryland Avenue MC 2007, The University of Chicago, Chicago, IL 60637; e-mail: jdignam{at}health.bsd.uchicago.edu

In clinical cancer research, competing risks are frequently encountered. For example, individuals undergoing treatment for surgically resectable disease may experience recurrence near the removed tumor, metastatic recurrence at other sites, occurrence of second primary cancer, or death resulting from noncancer causes before any of these events. Two quantities, the cause-specific hazard function and the cumulative incidence function, are commonly used to summarize outcomes by event type. Tests for event-specific differences between treatment groups may thus be based on comparison of (a) cause-specific hazards via a log-rank or related test, or (b) the cumulative incidence functions via one of several available tests. Inferential results for tests based on these different metrics can differ considerably for the same cause-specific end point. Depending on the questions of principal interest, one or both metrics may be appropriate to consider. We present simulation study results and discuss examples from cancer clinical trials to illustrate these points and provide guidance for analysis when competing risks are present.

Supported in part by Public Health Service Grants No. NCI P30-CA-14599 and NCI-U10-CA-69651 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. W. Evans, J.-P. Ryckelynck, E. Fabre, and C. Verger Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account Nephrol. Dial. Transplant., January 25, 2010; (2010): gfq003v1 - gfq003. [Abstract] [Full Text] [PDF]